Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARCT Arcturus Therapeutics	$13.01 -2.4%	$12.40	$8.04 ▼ $25.88	$361.52M	2.3	423,673 shs	656,158 shs
HRTX Heron Therapeutics	$2.07 -3.3%	$2.06	$1.04 ▼ $3.73	$326.49M	1.16	2.19 million shs	1.46 million shs
RVNC Revance Therapeutics	$3.65	$3.65	$2.40 ▼ $6.65	$381.02M	0.9	3.58 million shs	N/A
STOK Stoke Therapeutics	$11.35 -2.4%	$10.27	$5.35 ▼ $16.15	$634.96M	1.09	672,883 shs	509,358 shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARCT Arcturus Therapeutics	-2.40%	+4.00%	+3.01%	+37.96%	-46.57%
HRTX Heron Therapeutics	-3.27%	-1.90%	+9.52%	-1.90%	-40.86%
RVNC Revance Therapeutics	0.00%	0.00%	0.00%	0.00%	+42.02%
STOK Stoke Therapeutics	-2.41%	-2.07%	+18.11%	+82.18%	-15.99%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARCT Arcturus Therapeutics	3.6053 of 5 stars	4.6	2.0	0.0	2.7	2.5	0.6
HRTX Heron Therapeutics	4.0739 of 5 stars	3.5	0.0	4.2	4.4	1.7	0.6
RVNC Revance Therapeutics	2.6963 of 5 stars	3.1	0.0	4.7	0.0	1.7	0.6
STOK Stoke Therapeutics	3.996 of 5 stars	3.6	0.0	4.8	2.5	0.8	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARCT Arcturus Therapeutics	3.11	Buy	$53.50	311.22% Upside
HRTX Heron Therapeutics	3.00	Buy	$5.00	141.55% Upside
RVNC Revance Therapeutics	2.13	Hold	$8.45	131.51% Upside
STOK Stoke Therapeutics	3.29	Buy	$23.20	104.41% Upside

Current Analyst Ratings Breakdown

Latest RVNC, STOK, ARCT, and HRTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/1/2025	STOK Stoke Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$22.00
6/9/2025	HRTX Heron Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$6.00
5/28/2025	ARCT Arcturus Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sector Outperform	$32.00
5/14/2025	ARCT Arcturus Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$50.00 ➝ $45.00
5/14/2025	STOK Stoke Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/14/2025	STOK Stoke Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$47.00 ➝ $35.00
5/13/2025	ARCT Arcturus Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/13/2025	ARCT Arcturus Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$68.00 ➝ $66.00
4/11/2025	HRTX Heron Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00 ➝ $4.00
4/10/2025	ARCT Arcturus Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$60.00 ➝ $60.00
4/9/2025	STOK Stoke Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$22.00 ➝ $22.00

(Data available from 7/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARCT Arcturus Therapeutics	$152.31M	2.32	N/A	N/A	$8.90 per share	1.46
HRTX Heron Therapeutics	$144.29M	2.19	N/A	N/A	($0.22) per share	-9.41
RVNC Revance Therapeutics	$234.04M	1.63	N/A	N/A	($1.73) per share	-2.11
STOK Stoke Therapeutics	$190.91M	3.25	N/A	N/A	$4.32 per share	2.63

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARCT Arcturus Therapeutics	-$80.94M	-$2.53	N/A	N/A	N/A	-47.47%	-27.41%	-19.01%	8/4/2025 (Estimated)
HRTX Heron Therapeutics	-$13.58M	-$0.06	N/A	N/A	N/A	-5.24%	N/A	-3.43%	8/5/2025 (Estimated)
RVNC Revance Therapeutics	-$323.99M	-$1.93	N/A	N/A	N/A	-74.67%	N/A	-37.22%	8/6/2025 (Estimated)
STOK Stoke Therapeutics	-$88.98M	$0.79	14.37	N/A	N/A	26.33%	19.08%	15.72%	8/5/2025 (Estimated)

Latest RVNC, STOK, ARCT, and HRTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/12/2025	Q1 2025	ARCT Arcturus Therapeutics	-$1.58	-$0.52	+$1.06	-$0.52	$25.64 million	$29.38 million
5/6/2025	Q1 2025	HRTX Heron Therapeutics	-$0.01	$0.01	+$0.02	$0.01	$37.08 million	$38.90 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARCT Arcturus Therapeutics	N/A	N/A	N/A	N/A	N/A
HRTX Heron Therapeutics	N/A	N/A	N/A	N/A	N/A
RVNC Revance Therapeutics	N/A	N/A	N/A	N/A	N/A
STOK Stoke Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARCT Arcturus Therapeutics	0.06	5.64	5.64
HRTX Heron Therapeutics	N/A	2.40	1.76
RVNC Revance Therapeutics	N/A	4.12	3.05
STOK Stoke Therapeutics	N/A	8.41	8.41

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARCT Arcturus Therapeutics	94.54%
HRTX Heron Therapeutics	80.01%
RVNC Revance Therapeutics	97.70%
STOK Stoke Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
ARCT Arcturus Therapeutics	15.30%
HRTX Heron Therapeutics	5.86%
RVNC Revance Therapeutics	5.10%
STOK Stoke Therapeutics	9.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARCT Arcturus Therapeutics	180	27.12 million	22.97 million	Optionable
HRTX Heron Therapeutics	300	152.56 million	143.62 million	Optionable
RVNC Revance Therapeutics	500	104.39 million	99.07 million	Optionable
STOK Stoke Therapeutics	100	54.60 million	49.41 million	Optionable

RVNC, STOK, ARCT, and HRTX Headlines

Recent News About These Companies

Stoke Therapeutics' (STOK) "Buy" Rating Reaffirmed at Needham & Company LLC

1 hour ago | marketbeat.com

Michelin’s Stoke-on-Trent plant set to lower CO2 emissions with tyre reprocessing site

July 1 at 3:34 AM | thebusinessdesk.comT

Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives Average Rating of "Buy" from Analysts

June 30 at 2:29 AM | marketbeat.com

STOK Stoke Therapeutics, Inc. - Seeking Alpha

June 29 at 9:44 AM | seekingalpha.com

Analysts Are Bullish on These Healthcare Stocks: Apogee Therapeutics (APGE), Legend Biotech (LEGN)

June 28 at 3:13 PM | theglobeandmail.com

Stoke-on-Trent bungalow could be turned into children's home

June 28 at 10:12 AM | msn.com

Stoke City confirm new coach appointment as pre-season starts

June 27, 2025 | msn.com

Traditional Stoke-on-Trent pub reopens for the first time since Covid

June 27, 2025 | stokesentinel.co.ukS

Stoke Therapeutics (NASDAQ:STOK) Trading Down 3.5% - Here's Why

June 26, 2025 | marketbeat.com

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 17, 2025 | businesswire.com

STOK FY2025 EPS Forecast Lowered by Cantor Fitzgerald

June 16, 2025 | marketbeat.com

Stoke Therapeutics: Impressive Pipeline And Big Backers

June 15, 2025 | seekingalpha.com

Assenagon Asset Management S.A. Sells 391,322 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK)

June 15, 2025 | marketbeat.com

Cantor Fitzgerald Predicts STOK FY2026 Earnings

June 10, 2025 | marketbeat.com

Kangaroo Care Awareness Day celebrated at Stoke Mandeville Hospital

June 10, 2025 | msn.com

Jong Oranje and Stoke City star is open to transfer: “Of course, I have my ambitions”

June 10, 2025 | sports.yahoo.com

Stoke City confirm next stage of major badge consultation

June 10, 2025 | msn.com

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Increases Stock Holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK)

June 10, 2025 | marketbeat.com

Stoke Therapeutics, Inc. (NASDAQ:STOK) Shares Sold by Two Sigma Investments LP

June 9, 2025 | marketbeat.com

Jane Street Group LLC Sells 318,465 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK)

June 8, 2025 | marketbeat.com

Stoke City Secure Youth International Amid Leeds United Interest

June 7, 2025 | therealefl.co.ukT

New MarketBeat Followers Over Time

Media Sentiment Over Time

RVNC, STOK, ARCT, and HRTX Company Descriptions

Arcturus Therapeutics NASDAQ:ARCT

$13.01 -0.32 (-2.40%)

Closing price 06/30/2025 04:00 PM Eastern

Extended Trading

$12.94 -0.07 (-0.54%)

As of 08:49 AM Eastern

Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

Heron Therapeutics NASDAQ:HRTX

$2.07 -0.07 (-3.27%)

Closing price 06/30/2025 04:00 PM Eastern

Extended Trading

$2.08 +0.01 (+0.48%)

As of 08:57 AM Eastern

Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.

Revance Therapeutics NASDAQ:RVNC

$3.65 0.00 (0.00%)

As of 02/6/2025

Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing OnabotulinumtoxinA, a biosimilar to BOTOX that is in preclinical stage. The company also offers Resilient Hyaluronic Acid (RHA) dermal filler for the correction of moderate to severe dynamic facial wrinkles; and RHA Redensity, a dermal filler for the treatment of moderate to severe dynamic perioral rhytids. It has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.

Stoke Therapeutics NASDAQ:STOK

$11.35 -0.28 (-2.41%)

Closing price 06/30/2025 04:00 PM Eastern

Extended Trading

$11.46 +0.11 (+0.97%)

As of 08:51 AM Eastern

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time